<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966145</url>
  </required_header>
  <id_info>
    <org_study_id>4RTNI-2</org_study_id>
    <secondary_id>2R01AG038791-06A1</secondary_id>
    <nct_id>NCT02966145</nct_id>
  </id_info>
  <brief_title>4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2</brief_title>
  <acronym>4RTNI-2</acronym>
  <official_title>The Four-Repeat Tauopathy Neuroimaging Initiative</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to identify the most reliable methods of analysis for tracking CBD,
      PSP, and o/vPSP over time. The results from this study may be used in the future to calculate
      statistical power for clinical drug trials. The study will also provide information about the
      relative value of novel imaging techniques for diagnosis, as well as the value of imaging
      techniques versus testing of blood, urine, and cerebrospinal fluid (CSF) 'biomarkers'.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tau-PET Brain Scan</measure>
    <time_frame>Baseline, 1-year, and 2-years.</time_frame>
    <description>Change from Baseline of Tau protein distribution in the brain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amyloid-PET Brain Scan</measure>
    <time_frame>Baseline</time_frame>
    <description>Presence of Amyloid in the brain at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Volume on MRI</measure>
    <time_frame>Baseline, 6-months, 1-year, and 2-years.</time_frame>
    <description>Change from Baseline of brain tissue volume.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progressive Supranuclear Palsy Rating Scale (PSPRS)</measure>
    <time_frame>Baseline, 6-months, 1-year, and 2-years.</time_frame>
    <description>Change from Baseline of this rating scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Corticobasal Degeneration Functional Scale (CBDFS)</measure>
    <time_frame>Baseline, 6-months, 1-year, and 2-years.</time_frame>
    <description>Change from Baseline of this rating scale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eye Movement Function</measure>
    <time_frame>Baseline, 6-months, 1-year, and 2-years.</time_frame>
    <description>Change from Baseline of eye movement function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal Imaging</measure>
    <time_frame>Baseline, 6-months, 1-year, and 2-years.</time_frame>
    <description>Change from Baseline of retinal thickness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>UDS Neuropsychological Testing Battery, including supplemental FTLD Module</measure>
    <time_frame>Baseline, 6-months, 1-year, and 2-years.</time_frame>
    <description>Change fromm Baseline of cognitive function.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">232</enrollment>
  <condition>Corticobasal Degeneration (CBD)</condition>
  <condition>Corticobasal Syndrome (CBS)</condition>
  <condition>Cortical-basal Ganglionic Degeneration (CBGD)</condition>
  <condition>Progressive Supranuclear Palsy (PSP)</condition>
  <condition>Nonfluent Variant Primary Progressive Aphasia (nfvPPA)</condition>
  <condition>Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)</condition>
  <arm_group>
    <arm_group_label>PSP &amp; CBD</arm_group_label>
    <description>Observational study of participants with a diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration (also called Corticobasal Syndrome or Cortical-basal Ganglionic Degeneration).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>o/vPSP</arm_group_label>
    <description>Observational study of participants with a diagnosis of an oligosymptomatic or variant Progressive Supranuclear Palsy syndrome.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Volunteers</arm_group_label>
    <description>Observational study of participants with no known diagnosis of a neurological or neurodegenerative condition, and no known history of memory complaints.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational Study</intervention_name>
    <arm_group_label>PSP &amp; CBD</arm_group_label>
    <arm_group_label>o/vPSP</arm_group_label>
    <arm_group_label>Normal Volunteers</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, cell lines and cerebrospinal fluid (CSF) will be retained by study
      investigators and stored at NIH-funded repositories.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants diagnosed with Corticobasal Syndrome (CBS), Corticobasal Degeneration (CBD),
        Progressive Supranuclear Palsy, or Oligo- or Variant- Progressive Supranuclear Palsy
        (o/vPSP); Healthy Volunteers.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No known history of neurological disease, or meet criteria for one of the following:
             Corticobasal Syndrome or Degeneration (CBS or CBD); Progressive Supranuclear Palsy
             (PSP); or Oligo- or Variant- Progressive Supranuclear Palsy (o/vPSP)

          -  Needs a reliable study partner who has frequent contact with the participant, who is
             available to provide information about the participant, and who can accompany the
             participant to research visits as needed

          -  Must be willing and able to undergo testing procedures, which include longitudinal
             follow-up visits

          -  Must be able to walk five steps with minimal assistance

        Exclusion Criteria:

          -  Significant neurological disease other than CBD, PSP, or a variant PSP syndrome.

          -  Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or
             metal fragments or metal objects in the eyes, skin, or body

          -  In the site investigator's opinion, inability to complete sufficient key study
             procedures, or some other equivalent assessment of impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam L Boxer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan N Luong, BS</last_name>
    <phone>(415) 476-9578</phone>
    <email>Phi.Luong@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hilary Heuer, PhD</last_name>
    <phone>(415) 476-6743</phone>
    <email>Hilary.Heuer@ucsf.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, San Diego (UCSD)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Thomas, MS</last_name>
      <phone>858-822-5751</phone>
      <email>kkt008@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Irene Litvan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan N Luong, BS</last_name>
      <phone>415-476-9578</phone>
      <email>Phi.Luong@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harvard University - Massachusetts General Hospital</name>
      <address>
        <city>Charlestown</city>
        <state>Massachusetts</state>
        <zip>02129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Krivensky, BA</last_name>
      <phone>617-726-6205</phone>
      <email>SKrivensky@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Bradford C Dickerson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Dheel, BS</last_name>
      <phone>507-284-1324</phone>
      <email>Dheel.Christina@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Bradley F Boeve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Igne</last_name>
      <phone>215-662-3596</phone>
      <email>cigne@mail.med.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Murray Grossman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Namita Multani</last_name>
      <phone>(416) 507-6880</phone>
      <email>Namita.Multani@mail.utoronto.ca</email>
    </contact>
    <investigator>
      <last_name>Maria Carmela Tartaglia, MD, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Tröster AI, Vidailhet M, Weiner WJ. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013 Jan 29;80(5):496-503. doi: 10.1212/WNL.0b013e31827f0fd1.</citation>
    <PMID>23359374</PMID>
  </reference>
  <reference>
    <citation>Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, Doody RS, Lees A, Golbe LI, Williams DR, Corvol JC, Ludolph A, Burn D, Lorenzl S, Litvan I, Roberson ED, Höglinger GU, Koestler M, Jack CR Jr, Van Deerlin V, Randolph C, Lobach IV, Heuer HW, Gozes I, Parker L, Whitaker S, Hirman J, Stewart AJ, Gold M, Morimoto BH; AL-108-231 Investigators. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul;13(7):676-85. doi: 10.1016/S1474-4422(14)70088-2. Epub 2014 May 27.</citation>
    <PMID>24873720</PMID>
  </reference>
  <reference>
    <citation>Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol. 2011 Sep;68(9):1137-44. doi: 10.1001/archneurol.2011.105. Epub 2011 May 9.</citation>
    <PMID>21555603</PMID>
  </reference>
  <reference>
    <citation>Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain. 2007 Jun;130(Pt 6):1552-65. Epub 2007 Apr 2.</citation>
    <PMID>17405767</PMID>
  </reference>
  <reference>
    <citation>Heuer HW, Mirsky JB, Kong EL, Dickerson BC, Miller BL, Kramer JH, Boxer AL. Antisaccade task reflects cortical involvement in mild cognitive impairment. Neurology. 2013 Oct 1;81(14):1235-43. doi: 10.1212/WNL.0b013e3182a6cbfe. Epub 2013 Aug 28.</citation>
    <PMID>23986300</PMID>
  </reference>
  <reference>
    <citation>Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996 Jul;47(1):1-9. Review.</citation>
    <PMID>8710059</PMID>
  </reference>
  <reference>
    <citation>Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, Kramer JH, Rabinovici G, Ahlijanian M, Miller BL, Seeley W, Grinberg LT, Rosen H, Meredith J Jr, Boxer AL. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014 Jan;75(1):116-26. doi: 10.1002/ana.24052. Epub 2014 Jan 2.</citation>
    <PMID>24242746</PMID>
  </reference>
  <reference>
    <citation>Stamelou M, de Silva R, Arias-Carrión O, Boura E, Höllerhage M, Oertel WH, Müller U, Höglinger GU. Rational therapeutic approaches to progressive supranuclear palsy. Brain. 2010 Jun;133(Pt 6):1578-90. doi: 10.1093/brain/awq115. Epub 2010 May 14. Review.</citation>
    <PMID>20472654</PMID>
  </reference>
  <reference>
    <citation>Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, Basal Ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Semin Neurol. 2014 Apr;34(2):129-50. doi: 10.1055/s-0034-1377058. Epub 2014 Jun 25.</citation>
    <PMID>24963673</PMID>
  </reference>
  <reference>
    <citation>Wagshal D, Sankaranarayanan S, Guss V, Hall T, Berisha F, Lobach I, Karydas A, Voltarelli L, Scherling C, Heuer H, Tartaglia MC, Miller Z, Coppola G, Ahlijanian M, Soares H, Kramer JH, Rabinovici GD, Rosen HJ, Miller BL, Meredith J, Boxer AL. Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy. J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):244-50. doi: 10.1136/jnnp-2014-308004. Epub 2014 Jun 4.</citation>
    <PMID>24899730</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CBD</keyword>
  <keyword>CBS</keyword>
  <keyword>CBGD</keyword>
  <keyword>PSP</keyword>
  <keyword>nfvPPA</keyword>
  <keyword>oPSP</keyword>
  <keyword>vPSP</keyword>
  <keyword>o/vPSP</keyword>
  <keyword>Corticobasal Degeneration</keyword>
  <keyword>Corticobasal Syndrome</keyword>
  <keyword>Cortocal-basal Ganglionic Degeneration</keyword>
  <keyword>Progressive Supranuclear Palsy</keyword>
  <keyword>Nonfluent Variant Primary Progressive Aphasia</keyword>
  <keyword>Oligosymptomatic Progressive Supranuclear Palsy</keyword>
  <keyword>Variant Progressive Supranuclear Palsy</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Neuroimaging</keyword>
  <keyword>MRI</keyword>
  <keyword>PET</keyword>
  <keyword>Tau</keyword>
  <keyword>Oculomotor</keyword>
  <keyword>Retinal Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Aphasia</mesh_term>
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Tauopathies</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

